Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma

NCT05160584 is registered in ClinicalTrials.gov with Janssen Pharmaceutica N.V., Belgium as lead sponsor.

NCT NCT05160584
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05160584 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma
Lead sponsor
Janssen Pharmaceutica N.V., Belgium
Phase
Observational
Overall status
Recruiting
Start date
November 18, 2021
Completion date
October 30, 2028
Enrollment
300 (estimated)
Sites
90

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory multiple myeloma